Search Results - Mahobia, Vijay

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Efficacy and Safety of Paclitaxel versus Cisplatin with Concurrent Radiotherapy in Central India Patients with Locally Advanced Head-and-neck Cancers: A Randomized, Open-label Study

    Efficacy and Safety of Paclitaxel versus Cisplatin with Concurrent Radiotherapy in Central India Patients with Locally Advanced Head-and-neck Cancers: A Randomized, Open-label Stud... by Mahobia, Vijay, Pawar, Amol, Diwan, Ashok Kumar, Bandhate, Kamal

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial

    Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial by Prabhash, Kumar, Deshmukh, Chetan, Malhotra, Hemant, Sharma, Atul, Jain, Minish, Dhamne, Nilesh, Nagarakar, Rajnish, Ganesan, Prasantha, Mahobia, Vijay K, Das, Chandan K, Kumar, Rejnish, Shivanna, Prakash S, Avaronnan, Manu P, Chaithanya, Puligundla K, Chaudhary, Vaibhav, Singh, Kartar, Aagre, Suhas, Ravishankar, Bellala, Mehta, Dhruv, Shilpa, Kandipalli, Maniar, Vashishth, Chatterjee, Koushik, Majumdar, Saroj D, Dana, Rohitashwa, Noronha, Vanita, Menon, Nandini, Sharma, Akhilesh, Pawar, Roshan, Shahavi, Vinayaka, Yadav, Rajiv, Aiwale, Amol

    Published in JCO global oncology
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  3. 3
    A study to evaluate resource draining "no shows"

    A study to evaluate resource draining "no shows" by Chand, Alok Anil, Kamble, Krishna M, Diwan, Ashok K, Mahobia, Vijay K, Chand, Dipti Anil

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer

    A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metasta... by Kothari, Rushabh, Doshi, Maulik, Chaithanya, P.K., CT, Satheesh, Kumar, Anil, Mallavarapu, Krishna Mohan, Nagarkar, Rajnish, Mahobia, Vijay, Bhatt, Niraj, Priyadarshini, K.L., Gogia, Ajay, Maksud, Tanveer, Prasad, Saurabh, Velavan, K., L․K․, Rajeev, SS, Prakash, Talreja, Vikas, Kalra, Kaushal, Nemade, Bhushan, Dastidar, Aloke Ghosh, Gupta, Tarachand, Patil, Tushar, Bondarde, Shailesh, Patel, Pinakin, Gupta, Sudeep, Biswas, Ghanashyam, Vaghela, Manan, Mahato, Pinaki, Parekh, Honey, Kalloli, Mahesh, Shetty, Rachan, Prakash, Gaurav, Goel, Anil, Mandal, Srikrishna, Choudhury, Tamohan, Jain, Minish, Goswami, Chanchal, H․M․, Yathish Kumar, Mukherjee, K․K․, Shrivastava, Rahul, Parmar, Deven

    Published in Clinical breast cancer
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: